Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.77 USD | +5.60% | +11.54% | +154.73% |
May. 02 | Transcript : Cardiff Oncology, Inc., Q1 2024 Earnings Call, May 02, 2024 | |
May. 02 | Cardiff Oncology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Financials (USD)
Sales 2024 * | 390K | Sales 2025 * | 66.67K | Capitalization | 169M |
---|---|---|---|---|---|
Net income 2024 * | -45M | Net income 2025 * | -57M | EV / Sales 2024 * | 432 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 2,528 x |
P/E ratio 2024 * |
-3.86
x | P/E ratio 2025 * |
-3.56
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 92.33% |
Latest transcript on Cardiff Oncology, Inc.
1 day | +5.60% | ||
1 week | +11.54% | ||
Current month | -13.53% | ||
1 month | -17.86% | ||
3 months | +117.92% | ||
6 months | +255.66% | ||
Current year | +154.73% |
Managers | Title | Age | Since |
---|---|---|---|
Mark Erlander
CEO | Chief Executive Officer | 64 | 13-03-03 |
James Levine
DFI | Director of Finance/CFO | 53 | 21-07-11 |
Tod Smeal
CTO | Chief Tech/Sci/R&D Officer | 59 | 22-01-10 |
Members of the board | Title | Age | Since |
---|---|---|---|
James Armitage
BRD | Director/Board Member | 77 | 20-04-21 |
Gary Pace
BRD | Director/Board Member | 76 | 20-04-21 |
Mark Erlander
CEO | Chief Executive Officer | 64 | 13-03-03 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-16 | 3.77 | +5.60% | 498,727 |
24-05-15 | 3.57 | -0.28% | 336,262 |
24-05-14 | 3.58 | +2.87% | 844,336 |
24-05-13 | 3.48 | +2.65% | 341,899 |
24-05-10 | 3.39 | +0.30% | 471,847 |
Delayed Quote Nasdaq, May 16, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+154.73% | 160M | |
+33.37% | 49.46B | |
+1.55% | 42.58B | |
+49.11% | 42.49B | |
-4.22% | 29.09B | |
+11.57% | 26.61B | |
-21.00% | 18.64B | |
+7.36% | 13.16B | |
+28.30% | 12.55B | |
+23.80% | 12.1B |
- Stock Market
- Equities
- CRDF Stock